BOFAS VTE Position Statement BOFAS VTE Position Statement Updated Statement June 2025 20 July 2025 Click here to access the newly updated BOFAS Position Statement for VTE Prophylaxis Read more
Registration Open for BOFAS 2025 (Nov) Registration Open for BOFAS 2025 (Nov) Click to Register Now! 25 June 2025 Read more
New Speciality Standards New Speciality Standards Management of End Stage Ankle Arthritis 05 April 2025 Click here to access the latest BOFAS-BOA Standards for management of End Stage Ankle Arthritis Read more
2Oct2025 BOFAS Principles Course - Dubai 02/10/2025 - 04/10/2025 Read more The aim is to give Overseas Trainee Orthopaedic Surgeons a solid grounding in the principles and the decision making in Foot & Ankle Surgery. There is an emphasis on clinical examination of cases, small group discussions and learning surgical approaches in the cadaver lab. This is the first course BOFAS is running in UAE and the aim is to expand the Foot and Ankle education and training in the Middle East and Gulf area. Venue - Le Meridien, Dubai, United Arab Emirates Documents to download ACv3BOFAS-Principles-Course-Programme-DXB(.pdf, 2.13 MB) - 523 download(s) Read more
20Oct2025 BOFAS Principles Course Taunton 20/10/2025 - 21/10/2025 Read more These courses are aimed at Higher Surgical Trainees / ST3 onwards and are designed to teach the core of Foot and Ankle surgery in an informal and interactive environment. The emphasis is on clinical examination cases, discussion groups and typical day-to-day clinic scenarios. Although not an exam preparation course, content is taught to the standard expected in the FRCS(Tr & Orth) exam; that of a day-one non-specialist orthopaedic consultant. Applications will open on 1st September 2023. Venue - Taunton (TBC) Documents to download BOFAS-Course-Programme--Taunton-2025(.docx, 31.88 KB) - 764 download(s) Read more
Togay Koç / 08 July 2022 / Categories: Abstracts, 2015, Podium Metallic hemiarthroplasty for the treatment of end stage hallux rigidus: mid-term implant survival, functional outcome and cost analysis G. Dall, N. Clement, D. McDonald, I. Ahmed, A. Duckworth, H. Shalaby, J. McKinley Introduction: We present a review of 97 consecutive BioPro® metallic hemiarthroplasties performed in 80 patients for end-stage hallux rigidus, with a minimum of five years follow-up. Results: The mean age of the cohort was 55 (22 to 74) years. No patient was lost to follow-up. There were 15 revisions performed, one for infection, two for osteolysis, and 12 for pain. The all cause survival rate at five years was 85.6% (95% confidence interval (CI) 83.5 to 87.9). Younger age was a significant predictor of revision (odds ratio 1.09, 95% CI 1.02 to 1.17, p=0.014) on excluding infection and adjusting for confounding variables (Cox regression). Significant improvements were demonstrated at 5 years in the Manchester Oxford foot questionnaire (13.9, 95% CI 10.5 to 17.2) and in the physical component of the short form 12 score (6.5, 95% CI 4.1 to 8.9). The overall satisfaction rate was 72%. The cost per quality-adjusted-life-year at 5 years, accounting for a 3% per year revision rate, was £3,714. Conclusion: The BioPro offers good short to mid-term functional outcome and is a cost effective intervention. The relative high revision rate is associated with younger age and the use of this implant may be limited to older patients. Print 612 Tags: Hallux Rigidus